Advertisement
Mayo Clinic Proceedings Home
MCP Digital Health Home

46-Year-Old Woman With Type 2 Diabetes Mellitus and Obesity

      A 46-year-old woman presented to her internist for evaluation of type 2 diabetes mellitus (T2DM) and obesity.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sanyal A.J.
        • Chalasani N.
        • Kowdley K.V.
        • et al.
        Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
        N Engl J Med. 2010; 362: 1675-1685https://doi.org/10.1056/NEJMoa0907929
        • Apovian C.M.
        • Aronne L.J.
        • Bessesen D.H.
        • et al.
        Pharmacological management of obesity: an endocrine society clinical practice guideline.
        J Clin Endocrinol Metab. 2015; 100: 342-362https://doi.org/10.1210/jc.2014-3415
        • Nauck M.
        Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
        Diabetes Obes Metab. 2016; 18: 203-216https://doi.org/10.1111/dom.12591
        • Marso S.P.
        • Daniels G.H.
        • Brown-Frandsen K.
        • et al.
        Liraglutide and cardiovascular outcomes in type 2 diabetes.
        N Engl J Med. 2016; 375: 311-322https://doi.org/10.1056/NEJMoa1603827
        • Zelniker T.A.
        • Wiviott S.D.
        • Raz I.
        • et al.
        SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
        Lancet. 2019; 393: 31-39https://doi.org/10.1016/S0140-6736(18)32590-X
        • Gardner C.D.
        • Trepanowski J.F.
        • Del Gobbo L.C.
        • et al.
        Effect of low-fat vs low-carbohydrate diet on 12-month weight loss in overweight adults and the association with genotype pattern or insulin secretion.
        JAMA. 2018; 319: 667-679https://doi.org/10.1001/jama.2018.0245
        • Wilding J.P.H.
        • Batterham R.L.
        • Calanna S.
        • et al.
        Once-weekly semaglutide in adults with overweight or obesity.
        N Engl J Med. 2021; 384: 989-1002https://doi.org/10.1056/NEJMoa2032183
        • Aminian A.
        • Wilson R.
        • Zajichek A.
        • et al.
        Cardiovascular outcomes in patients with type 2 diabetes and obesity: comparison of gastric bypass, sleeve gastrectomy, and usual care.
        Diabetes Care. 2021; 44: 2552-2563https://doi.org/10.2337/dc20-3023
        • Yip S.
        • Plank L.D.
        • Murphy R.
        Gastric bypass and sleeve gastrectomy for type 2 diabetes: a systematic review and meta-analysis of outcomes.
        Obes Surg. 2013; 12: 1994-2003https://doi.org/10.1007/s11695-013-1030-z
        • Hayoz C.
        • Hermann T.
        • Raptis D.A.
        • et al.
        Comparison of metabolic outcomes in patients undergoing laparoscopic roux-en-Y gastric bypass versus sleeve gastrectomy: a systematic review and meta-analysis of randomised controlled trials.
        Swiss Med Wkly. 2018; 148w14633https://doi.org/10.4414/smw.2018.14633
        • Li L.
        • Yu H.
        • Liang J.
        • et al.
        Meta-analysis of the effectiveness of laparoscopic adjustable gastric banding versus laparoscopic sleeve gastrectomy for obesity.
        Medicine (Baltimore). 2019; 98e14735https://doi.org/10.1097/MD.0000000000014735
        • Papadia F.S.
        • Carlini F.
        • Rubartelli A.
        • et al.
        Diabetes resolution at 10 years after biliopancreatic diversion in overweight and class 1 obese patients with type 2 diabetes.
        Obes Surg. 2022; 32: 845-851https://doi.org/10.1007/s11695-021-05870-4
      CORRECT ANSWERS: 1. e. 2. b. 3. d. 4. a. 5. b.